These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9123022)

  • 1. Increased expression of ICAM-1 and VCAM-1 in the skin after administration of the first dose of OKT3.
    ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Pals ST
    Transplant Proc; 1997; 29(1-2):325-7. PubMed ID: 9123022
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased dermal expression of ICAM-1 and VCAM-1 after administration of OKT3 in man.
    Buysmann S; van Diepen FN; Surachno S; Pals ST; ten Berge RJ
    Clin Nephrol; 1996 Aug; 46(2):84-91. PubMed ID: 8869784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.
    Desai DM; Scandling JD; Knoppel C; Dafoe DC; Alfrey EJ
    Transplant Proc; 1998 Jun; 30(4):1552-4. PubMed ID: 9636630
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 5. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

  • 7. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
    VanderWerf BA
    Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 9. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.
    Woodle ES; Bluestone JA; Zivin RA; Jolliffe LK; Auger J; Xu D; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1369-70. PubMed ID: 9636555
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression of ICAM-1 and VCAM-1 in renal allograft rejection.
    Jeong HJ; Lee HH; Kim YS; Kim SI; Moon JI; Park K
    Transplant Proc; 1998 Nov; 30(7):2953-4. PubMed ID: 9838302
    [No Abstract]   [Full Text] [Related]  

  • 11. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
    Vasquez EM; Fabrega AJ; Pollak R
    Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215
    [No Abstract]   [Full Text] [Related]  

  • 12. Different expression of adhesion molecules ICAM-1 and VCAM-1 and activation markers MHC class II and IL-2R in acute and chronic rejection of rat kidney allografts.
    Kauppinen H; Soots A; Krogerus L; Brummer T; Ahonen J; Lautenschlager I
    Transplant Proc; 1997 Nov; 29(7):3150-1. PubMed ID: 9365703
    [No Abstract]   [Full Text] [Related]  

  • 13. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 14. The fate of renal allografts treated with OKT3 for steroid-resistant rejection.
    Veronese FV; Gonçalves LF; Vilarinho LL; Macedo VS; Manfro RC
    Transplant Proc; 1999 Nov; 31(7):3016-8. PubMed ID: 10578371
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
    Piatosa B; Grenda R; Prokurat S
    Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
    [No Abstract]   [Full Text] [Related]  

  • 16. Proliferation rate of cells in the interstitial infiltrate in acute kidney allograft rejection.
    Olsen S; Hansen HE
    Transplant Proc; 1996 Feb; 28(1):502-3. PubMed ID: 8644329
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract]   [Full Text] [Related]  

  • 18. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
    Kaiser BA; Palmer JA; Dunn SP; Mochon MA; Bartosh SM; Schulman SL; Polinsky MS; Baluarte HJ
    Child Nephrol Urol; 1991; 11(4):190-2. PubMed ID: 1777898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus in late acute OKT3-resistant and/or steroid-resistant rejection after simultaneous pancreas and kidney transplantation.
    Kahl A; Oppert M; Müller A; Settmacher U; Lepenies J; Klupp J; Kampf D; Neuhaus P; Frei U
    Transplant Proc; 2002 Sep; 34(6):2253-5. PubMed ID: 12270387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.